December 18th 2017
Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.
December 17th 2017
John Heinzerling, MD, discusses the impact of durvalumab and other developments in the treatment of patients with stage III non-small cell lung cancer.
December 16th 2017
Ferdinandos Skoulidis, MD, PhD, discusses potential treatment options for KRAS-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.
December 13th 2017
Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.
December 12th 2017
Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.
December 7th 2017
Hans Hammers, MD, PhD, discusses the game-changing combination of nivolumab and ipilimumab and highlighted other combinations that have potential in the treatment of patients with renal cell carcinoma.
December 6th 2017
Vincent K. Lam, MD, discusses the treatment paradigm for patients with ALK/ROS1-translocated NSCLC.
December 5th 2017
Jerry W. Mitchell, MD, discusses the use of medical marijuana as a chronic pain relief for patients with hematologic malignancies ad other tumor types.
December 4th 2017
George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.
Frank E. Mott, MD, discusses optimal treatment selection strategies for patients with NSCLC.
Melanie Majure, MD, discusses the optimal role chemotherapy for patients with TNBC and the importance of achieving a pCR.
November 30th 2017
Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.
November 29th 2017
Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.
November 27th 2017
Jacqueline Claudia Barrientos, MD, discusses the appropriate treatment strategies for elderly patients with chronic lymphocytic leukemia.
Susan R. Rheingold, MD, discusses the impact of CAR T-cell therapy on patients with ALL and options for patients who relapse on treatment.
Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.
November 23rd 2017
A. David McCollum, MD, discusses the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.
November 22nd 2017
Carlos Becerra, MD, discusses the current management and emerging therapies for patients with pancreatic cancer.
George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.
November 21st 2017
Jonathan Warner, MD, discusses the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.